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ABSTRACT
Aim of the study. This paper describes six cases of patients with myoclonus-dystonia syndrome who are members of a family 
in which an SGCE gene mutation has been confirmed.
Clinical rationale for the study. Myoclonus-dystonia syndrome is a very rare disease, with an incidence in Europe of about 2 in 
every million. Due to the fact that only a few case reports of this illness are accessible in the literature, the material we collected 
seems to be valuable for clinical practice.
Materials and methods. A history was taken, and physical and genetic examinations of the patients were performed. Further-
more, the clinical examination of three patients was video-recorded.
Results. The clinical picture of the disease varied significantly between the described individuals, from a healthy carrier of the 
SGCE mutation to patients presenting mild to moderate symptoms. The differences concerned the age at onset of the disease, 
the initial symptoms, the intensity of involuntary movements, and the predominant symptoms. In addition to the typical 
movement disorders which are myoclonus and dystonia, in the described family there was also the coexistence of epilepsy, 
obsessive-compulsive behaviour, dyslexia, dysgraphia, non-harmonious development of cognitive processes, as well as mild 
phenotypic features of muscular dystrophy. The mutation (NM_001099401.2:c.806-809delACTG) found in the presented family 
has not been described elsewhere.
Conclusions and clinical implications. Our description of six cases of patients demonstrates the heterogeneity of the natural 
course of the disease, even in patients with the same mutation. It seems reasonable to regularly examine relatives of patients 
with myoclonus-dystonia syndrome, who should be observed for involuntary movements as well as non-motor symptoms.
Key words: myoclonus-dystonia syndrome, MDS, DYT11, SGCE
(Neurol Neurochir Pol 2020; 54 (1): 33–38)
Introduction
Dystonia 11 (DYT11), or myoclonus-dystonia syndrome 
(MDS), is a genetically heterogeneous disorder inherited in an 
autosomal dominant manner with incomplete penetrance [1]. 
The gene associated with the development of the disease is the 
SGCE gene encoding ε-sarcoglycan, located on chromosome 
7q. However, mutations in the SGCE gene are present only in 
30–50% of patients with MDS [2, 3]. In the remaining cases, 
more than 50 different mutations have been identified, which 
demonstrates the genetic heterogeneity of the disease [4]. The 
incidence of DYT11 in Europe is about 2 in every million people 
[4, 5]. The disease usually appears in the first two decades of life. 
The symptoms include myoclonic jerking that co-occurs with 
dystonia. Myoclonus is the dominant symptom, which usually 
concerns the arms and axial muscles. Accompanying dystonia 
is usually mild, and often manifests itself as cervical dystonia or 
writer’s cramp [6] and occurs in more than 50% of patients [2]. 
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Clinical rationale for the study
This study is a description of six affected patients in 
a family with genetically confirmed myoclonus-dystonia 
syndrome, in whom the clinical picture of the disease varied 
significantly between individuals. Due to the fact that there 
are only a few case reports of this illness in the literature, the 
material we collected seems to be valuable for clinical practice. 
To the best of our knowledge, there have been no descriptions 
of other such families in Poland. 
Materials and methods
The authors (PJ, ZJ) personally examined three symptoma-
tic patients (IV:1, IV:2, II:6),  and one asymptomatic patient 
(III:2) and his spouse (III:1). Information about the other 
affected family members described here (II:1, II:3, III:7) was 
obtained from interviews with the examined patients and from 
the available medical documentation.
The patient’s genomic DNA was isolated from peripheral 
blood according to standard protocols (Epicentre, USA). 
Primers for eight exons of the SGCE gene and their flanking 
regions were designed using the online available programme 
FastPCR, based on the sequence of the SGCE-01 transcript 
in the ENSEMBL database, using previously described 
methodology [3]. Prior to subsequent analyses, the PCR 
products were checked by agarose gel electrophoresis. In 
order to avoid the background signal, the PCR products 
before direct sequencing were purified on Clean-Up columns 
(A & A Biotechnology, Poland). Although the SGCE gene 
consists of 13 exons, only eight exons were tested in this 
study. The following exons were excluded from testing: exons 
1 and 10 (rare splicing variants); exon 11, because none of 
the known mutations have ever been detected in this exon; 
and exons 9b and 11b, as they are subject to alternative 
splicing [7]. 
Results
Symptoms of the disease occurred in six members 
of the described family; 13 other family members were 
healthy (Fig.1).
Case 1 (IV:1, video) is a 22 year-old woman who developed 
the first symptoms of the disease at 18 months. She was a child 
of a first, normal pregnancy, born at 40 weeks, receiving 9 po-
ints on the Apgar scale after birth. The presenting symptom of 
the disease was myoclonus of the hand. A few years later, the 
symptoms of dystonia occurred. At the time of examination, 
the dominant symptom was head myoclonus. Moreover, we 
also noticed neck myoclonus, sporadic trunk myoclonus that 
involved the axial muscles, as well as cervical dystonia and mild 
writer’s cramp. There was a remarkable reaction to alcohol — 
its consumption caused transient relief of myoclonus. Motor 
symptoms were quite mild and the course of the disease was 
initially progressive, then stationary. Difficulties in writing 
and performing manual work had been observed from child-
hood. At the age of six, the patient underwent a psychological 
examination and was diagnosed as having normal mental 
development. At the age of eight, her intellectual abilities were 
assessed as average and within the normal range. At the age of 
15, a psychological and pedagogical opinion was issued due 
to school difficulties. In this evaluation, average intellectual 
abilities were found with a very non-harmonious development 
of cognitive processes — cause-and-effect thinking and 
graphomotor skills were well formed, verbal functions had 
developed at an average level, but arithmetic reasoning was 
at a decreased level, as was the range and durability of long-
-term memory processes and direct auditory memory. The 
examination also revealed specific difficulties in reading and 
writing, which at the average level of intellectual development 
was diagnosed as developmental dyslexia. In addition, mild 
obsessive-compulsive behaviour was diagnosed. In the past, 
there had been also one episode of a loss of consciousness, 
Figure 1. Pedigree. Women indicated by a circle, men indicated by a square; symbol with a slash indicates deceased individual. Filled sym-
bols indicate clinically affected individuals, and unfilled symbols indicate unaffected individuals. Individuals marked with an asterisk were 
evaluated clinically and genetically tested. Arrow points to the proband
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which was considered generalised epilepsy with absence 
seizures, due to observed generalised epileptic changes in the 
EEG increasing after hyperventilation and photostimulation. 
In EEG recordings performed on several occasions over her 
lifetime, a series of high-voltage slow waves, sharp waves, 
complexes of sharp and slow waves, as well as spikes and wave 
complexes had been revealed. No abnormalities were found 
during neuro-imaging. The patient was temporarily treated 
with clonazepam in doses of 0.5 mg twice a day. Treatment was 
withdrawn due to its negligible effect, quite mild movement 
symptoms, and the risk of addiction due to the long-term use 
of benzodiazepines. Based on genetic testing, a mutation in 
the SGCE gene was found in the patient. 
Case 2 (IV:2, video) is a 15 year-old boy who developed the 
first symptoms of the disease at the age of 2 years 6 months. He 
was a child of a second, normal pregnancy, born at 40 weeks, 
receiving 7/9/9 points on the Apgar scale. The first symptom 
of the disease was hand myoclonus. A few years later, symp-
toms of dystonia occurred. At the time of examination, the 
dominant symptom was hand myoclonus. Moreover, there 
was cervical dystonia, moderate writer’s cramp which caused 
objects to occasionally fall out of the hand, a dystonic hand 
position, as well as myoclonus of the head, arms and hands. 
Due to the young age of the patient, a reaction to alcohol was 
not established. Motor symptoms were moderate, and the co-
urse of the disease was initially progressive, and subsequently 
stable. In addition, the patient had developed mild obsessive-
-compulsive symptoms and specific abnormalities of school 
skills in writing (dysgraphia) and reading (dyslexia). At the 
age of 14, the patient underwent a psychological examination. 
Intellectual abilities were assessed as below average, but within 
the normal range, with an IQ score of 80. Generalised epilepsy 
with absence seizures was also diagnosed. In the PET-CT scan 
of the brain, a slightly increased FDG metabolism was found in 
deep structures on the left side. Furthermore, a symmetrically 
reduced metabolism was found in the medial parts of both 
temporal lobes. On physical examination, a supraclavicular 
triangle, gothic palate, a lower right palatal arch, with the 
tongue slightly turned to the left, were noticed. The patient 
choked from time to time. The diagnostics were extended to 
include an electromyographic examination, obtaining a re-
cord of the muscles under investigation, which may suggest 
discrete myogenic changes. Creatine kinase activity was 
83 U/L. Subsequently, a biopsy of the left quadriceps muscle 
was performed in which myopathic lesions were not confir-
med. The patient was temporarily treated with clonazepam in 
doses of 0.5mg twice a day. Treatment was withdrawn due to 
its negligible effect, moderate movement symptoms, and the 
risk of addiction due to the long-term use of benzodiazepines. 
Based on genetic testing, a mutation in the SGCE gene was 
found in the patient. 
Case 3 (II:6, video) is a 79 year-old woman, in whom at the 
age of about 35 the first symptoms of the disease had appeared 
in the form of involuntary movements of the head and lower 
limbs. The dominant symptom at the time of evaluation was 
irregular head tremor varying in amplitude and frequency 
which was assessed as dystonic tremor. Moreover, there was 
cervical dystonia (retrocollis), positional and kinetic hand tre-
mor, as well as a trembling mouth and voice. On examination, 
there was noticeable slowness of movements, which however 
did not meet the criteria of bradykinesia. Based on genetic 
testing, a mutation in the SGCE gene was found in the patient. 
Case 4 (II:1) is a woman in whom at the age of about 
seven years the first symptoms of the disease appeared. The 
predominant symptom in this patient was limb myoclonus. 
Case 5 (II:3) is a woman in whom the first symptoms of 
the disease appeared at the age of about 30. These included 
head and upper limb myoclonus.
Case 6 (III:7) is a woman in whom the first signs of the 
disease in the form of hand myoclonus appeared at the age 
of about 15.
A summary of the clinical and genetic findings is set out 
in Table 1.
Five patients (II:6; III:1; III:2; IV:1; IV:2) were tested for 
mutations in the SGCE gene (ENSG00000127990). In four 
patients (II:6; III:2; IV:1; IV:2), a novel mutation was found: 
according to HGVS nomenclature NM_001099401.2:c.806-
-809delACTG, according to Ensembl nomenclature c.806-
-809del (Transcript ID: ENST00000445866.7). This mutation 
leads to the deletion of codons encoding aspartic acid and 
tryptophan and reading frame shift. A so-called frameshift 
mutation means that triplets of nucleotides (codons), after 
the mutation, code different amino acids. In this case, the 
mutation altered the STOP codon in the sequence, leading to 
the creation of an abnormally short SGCE polypeptide.
Discussion
This paper describes cases of MDS in patients who are re-
lated to each other. The same mutation of the SGCE gene being 
the cause of myoclonus-dystonia syndrome has been identified 
in all family members who have been genetically tested. 
Patients exhibited significant variations in their clinical 
picture. Differences concerned the age at disease onset, as 
well as the type and severity of symptoms, from a healthy 
carrier of the mutation to patients presenting with mild to 
moderate symptoms. Motor symptoms in all six patients 
were typical for MDS, but each presented with different 
distributions and severity. Although the mutations in the 
SGCE gene are inherited in an autosomal dominant manner 
[8, 9], one (III:2) of the carriers of the mutation did not have 
any symptoms of myoclonus-dystonia syndrome. The prob-
able explanation is the phenomenon of so-called maternal 
imprinting, which has been observed in some families with 
MDS. According to the data in the literature, almost all 
children who inherit the mutation from their father develop 
symptoms. However, if inheritance is from the mother, the 
development of symptoms is observed in only about 5% 
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Table 1. A summary of the clinical and genetic findings
Case/sex Age at 
onset 
[years]
Type of invo-
luntary move-
ment
Distribution 
of myoclonus
Distribution 
of dystonia
Course of 
disease
SGCE gene 
mutation
Accompanying symp-
toms
1/F (IV:1) 1.5 myoclonus, 
dystonia
hand, head, 
neck, trunk, 
axial muscles
neck, hand stationary + developmental dyslexia, 
OCB, generalised epilep-
sy with absence seizures
2/M (IV:2) 2.5 myoclonus, 
dystonia
hands, head, 
shoulders
neck, hand stationary + dyslexia, dysgraphia, 
OCB, generalised 
epilepsy  with absence  
seizures, some features 
of muscle dystrophy
3/F   (II:6) 35 dystonia, tremor – head, neck stationary + slowness of movements
4/F   (II:1) 7 myoclonus limbs not known not known not known not known
5/F   (II:3) 30 myoclonus head, upper 
limbs
not known not known not known not known
6/F   (III:7) 15 myoclonus hands not known not known not known not known
F — female; M — male; OCB — obsessive-compulsive behaviour
Figure 2. Results of direct sequencing (fluorogram); A — patient with mutation of SGCE gene; B — healthy control
A
B
of children [10]. Patient III:2 inherited the mutation from 
the sick mother and did not present the phenotype of the 
disease. Due to probable maternal imprinting, his mutant 
SGCE gene allele is probably methylated (inactive), hence he 
did not develop the symptoms of the disease. The patient’s 
children, however, both have the NM_001099401.2:c.806-
809delACTG mutation and developed symptoms of the 
disease, which may indicate that the mutant alleles were no 
longer methylated. 
In six affected family members, the age at onset varied from 
1.5 to 35 years with the mean onset of symptoms at 15.2 years. 
In two patients, the first symptoms of the disease appeared 
after the age of 30, which is rare in MDS, because the disease 
appears typically in childhood with average onset of symptoms 
at 6 years [11]. Foncke et al., among 20 symptomatic patients, 
observed the late onset of the disease in only three patients 
(aged 43, 60, and 75 years) [12]. In the siblings described in 
our paper (IV:1, IV:2), the sister’s symptoms developed ear-
lier, which is a typical phenomenon — the symptoms appear 
earlier in girls [13]. 
Myoclonus occurred in five patients, and one did not 
present this kind of involuntary movement (Tab. 1). Hand 
myoclonus occurred in three patients, in two of them it 
was the first symptom of the disease, and in one of these 
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two persons it was the dominant symptom. Head myoclonus 
occurred in three people, and in one of them it was the main 
symptom of the disease. One patient presented myoclonus of 
the neck, trunk and axial muscles, one patient had myoclonus 
of the shoulders, and two patients had limb myoclonus. One 
patient presented a remarkable reaction to alcohol in the form 
of the resolution of myoclonus, which is characteristic of MDS: 
in most cases, alcohol consumption lessens the symptoms [6]. 
In the other five cases, the reaction to alcohol was unknown. 
Dystonia was diagnosed in three patients; the other three 
did not undergo a personal neurological examination, which 
makes it impossible to be certain whether they had this move-
ment disorder. In two patients, dystonia appeared only several 
years after the onset of the disease, but in one patient it was one 
of the first symptoms. All three patients had cervical dystonia. 
One patient presented additionally with mild writer’s cramp; 
in one patient this focal dystonia was more severe and was ac-
companied by occasional dropping of objects from the hands 
and dystonic positioning of the hand. One person suffered 
from significant dystonic head tremor.
Tremor was found in one of the six patients. Dystonic head 
tremor was the predominant symptom of the disease in this 
patient, and there was also a positional and kinetic tremor of 
the hands, and a mouth and voice tremor.
In addition to the typical movement disorders in the de-
scribed family, the coexistence of additional symptoms was 
noted. Two of the six patients were diagnosed with generalised 
epilepsy with absence seizures. In the literature there are single 
descriptions of families, members of whom had not only the 
typical movement symptoms of MDS but were also diagnosed 
with epilepsy. Such a family was described by Foncke et al. 
[12]. They observed the symptoms of epilepsy and/or EEG 
abnormalities associated with the movement symptoms of the 
disease in three out of five patients with confirmed mutations 
of the SGCE gene. Members of this family presented various 
types of seizures. One person had episodes of amnesia lasting 
for a few seconds, several times a day. A second person suf-
fered from epilepsy in the form of a strange odour sensation 
with a subsequent panic attack. This patient had episodes of 
evolution to complex partial seizures with reduced conscious-
ness (according to ILAE 2017 Classification: focal impaired 
awareness seizures) and several times secondary generalisa-
tion (according to ILAE 2017 Classification: focal to bilateral 
tonic-clonic seizures). The presentation of epilepsy in a third 
member of this family was reduced consciousness, consisting 
of staring and lack of communication. Seizures in this patient 
were similar to those presented by the patients described in 
our paper [14]. 
Two patients were diagnosed with obsessive-compulsive 
behaviour. There are cases in the literature concerning the 
coexistence in MDS of movement disorders with psychiatric 
disorders i.e. depression, anxiety disorders, obsessive-compul-
sive disorder, personality disorders, addictions, and attention 
deficit hyperactivity disorder (ADHD) [6].
Two patients presented specific disorders in terms of 
school skills: one was diagnosed with developmental dyslexia, 
the other with dyslexia and dysgraphia. To the best of our 
knowledge, there have been no reports in the literature to date 
regarding incidences of dyslexia and dysgraphia in patients 
with myoclonus-dystonia syndrome.
One patient had undergone a psychological examination 
several times during her life, while another had undergone 
a psychological examination only once. The other patients 
were not assessed by a psychologist. The intellectual abili-
ties of one evaluated patient (IV:1) were at an average level, 
with a very non-harmonious development of cognitive 
processes, whereas the intellectual abilities of another 
patient (IV:2) were below average, but within the normal 
range. There are different reports on the occurrence of 
cognitive impairment in patients with myoclonus-dystonia 
syndrome. Some authors do not recognise cognitive impair-
ment in this group of patients. However, there have been 
reports of cases of above-average verbal functioning with 
the simultaneous impairment of memory and executive 
functions. Coughlin et al. described the case of a 21 year-
old woman with a documented mutation in the SGCE gene 
in which the clinical presentation of the disease consisted 
of generalised myoclonus, cervical dystonia and writer’s 
cramp, and in which the symptoms were accompanied by 
intellectual disability [15]. 
One patient (IV:2) from our described family presented 
mild phenotypic features of myopathy: supraclavicular tri-
angle, gothic palate, and periodic choking. The patient has 
a mutation in the SGCE gene, which is located in the chromo-
somal region 7q21-q31 [2]. It is interesting that there is a locus 
nearby for the genes responsible for the formation of two 
forms of autosomal dominant inherited limb-girdle muscular 
dystrophy: LGMD 1D in locus 7q36 and LGMD 1F in locus 
7q32 [16]. The SGCE gene encodes the ε-sarcoglycan protein, 
which is one of the six isoforms of the transmembrane gly-
coprotein, while mutations of the genes encoding the other 
four isoforms of this protein (α-, β-, γ- and δ-sarcoglycan) 
are associated with the occurrence of limb-girdle dystrophies 
[2]. Although some mild myopathic changes were found on 
electromyography, muscle biopsy did not confirm dystrophic 
or myopathic changes. Genetic testing of LGMD was not 
performed. 
Clinical implications
Our description of six cases of patients with myoclonus-
-dystonia syndrome demonstrates the heterogeneity of the 
natural course of the disease, even in patients with the same 
mutation. To the best of our knowledge, the mutation which 
was found in the described family has not been reported pre-
viously. It seems reasonable to regularly examine relatives of 
patients with MDS, who should be observed for involuntary 
movements as well as non-motor symptoms. 
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